{"publication_id":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","doi":"10.1093/eurjpc/zwab173","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","doi":"10.1161/jaha.119.015716","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","doi":"10.1093/ckj/sfad082","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}